One or more of the required application components couldn’t be loaded. Please, refresh the page.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
5:32 AM
Theme 		Help

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

WGRX

Wellgistics Health Inc

Last Close
Apr 04 • 04:00PM ET
4.11
Dollar change
-0.40
Percentage change
-8.87%
Healthcare • Pharmaceutical Retailers • USA • NASD
WGRX - Stock Price Chart
Scroll to Statements
Index- P/E- EPS (ttm)-0.13 Insider Own85.20% Shs Outstand51.94M Perf Week7.59%
Market Cap213.47M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float7.69M Perf Month41.72%
Income-6.86M PEG- EPS next Q- Inst Own- Short Float0.20% Perf Quarter-
Sales18.13M P/S11.77 EPS this Y- Inst Trans0.20% Short Ratio0.10 Perf Half Y-
Book/sh0.13 P/B31.70 EPS next Y- ROA-23.78% Short Interest0.02M Perf Year-
Cash/sh0.02 P/C207.26 EPS next 5Y- ROE-357.65% 52W Range2.32 - 5.69 Perf YTD7.87%
Dividend Est.- P/FCF- EPS past 5Y- ROI-35.55% 52W High-27.77% Beta-
Dividend TTM- Quick Ratio0.13 Sales past 5Y0.00% Gross Margin3.60% 52W Low77.16% ATR (14)0.66
Dividend Ex-Date- Current Ratio0.38 EPS Y/Y TTM-136.98% Oper. Margin-33.90% RSI (14)50.91 Volatility15.41% 19.94%
Employees- Debt/Eq3.73 Sales Y/Y TTM- Profit Margin-37.82% Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq1.86 EPS Q/Q-302.90% Payout- Rel Volume0.32 Prev Close4.51
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume164.05K Price4.11
SMA207.21% SMA5017.08% SMA20017.08% Trades Volume54,775 Change-8.87%
Mar-27-25 08:05AM
Wellgistics Health Annual Letter to Shareholders From the Office of the CEO March 2025
(GlobeNewswire)
Mar-18-25 07:40AM
Wellgistics Health Achieves SOC 2 Type 1 Compliance, Strengthening Security for AI-Driven Pharmacy Solutions and Employer-Based Healthcare Models
(GlobeNewswire) +14.61%
Mar-04-25 05:18PM
Wellgistics Health, Inc. Announces Leadership Transition: Brian Norton Appointed as CEO Following Tim Canning's Departure
(GlobeNewswire)
07:40AM
Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND
(GlobeNewswire)
Feb-26-25 07:40AM
Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market
(GlobeNewswire)
01:15PM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Feb-25-25 01:15PM
D. Boral Capital Served as Joint Bookrunner to Wellgistics Health, Inc. (Nasdaq: WGRX) in connection with its $4.0 Million Initial Public Offering
(ACCESS Newswire) -9.90%
Feb-24-25 04:05PM
Wellgistics Health, Inc. Announces Closing of $4.0 Million Initial Public Offering
(GlobeNewswire) -20.47%
Feb-21-25 08:05AM
Wellgistics Health, Inc. Announces Pricing of $4.0 Million Initial Public Offering
(GlobeNewswire)
Wellgistics Health, Inc. operates as a holding company centered around pharmaceuticals and healthcare services. Its business portfolio consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. The company was founded by Ajjarapu Surendra on September 6, 2022 and is headquartered in Tampa, FL.
Income Statement • Balance Sheet • Cash Flow

Data

Timeframe

PeriodTTMFY 2024FY 2023FY 2022
Period End Date—12/31/202412/31/202312/31/2022
Period Length12 Months12 Months12 Months

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.

Learn more
Total Revenue
18.1318.130.00
Cost of Goods Sold Incl. D&A
17.4817.480.00
Gross Profit
0.650.650.00
Selling, General and Administrative Excl. Other
6.806.802.88
Research and Development
———
Other Operating Expense
0.000.000.00
Operating Income
-6.15-6.15-2.88
Interest Expense
0.830.830.02
Unusual Expense
0.000.000.00
Net Income Before Taxes
-6.86-6.86-2.90
Income Taxes
0.000.000.00
Consolidated Net Income
-6.86-6.86-2.90
Net Income From Continuing Operations
-6.86-6.86-2.90
Net Income
-6.86-6.86-2.90
EPS (Recurring)
-0.13-0.13-0.06
EPS (Basic, Before Extraordinaries)
-0.13-0.13-0.06
EPS (Diluted)
-0.13-0.13-0.06
EBITDA
-5.03-5.03-2.88
Price To Earnings Ratio
-31.14-31.14—
Price To Sales Ratio
———
Gross Margin
3.603.60—
Operating Margin
-33.90-33.90—
Net Margin
-37.82-37.82—
Shares Outstanding
51.9451.9451.94
Market Capitalization
213.49213.49—
values in Millions, USD
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.